The clinical integrity of the information provided by New Blue Health is upheld by our rigorous Medical Review Policy. This policy is the cornerstone of our commitment to patient safety and clinical accuracy, ensuring that every medical claim, therapeutic description, and safety guideline published on our platform has been vetted by highly qualified healthcare professionals.
Our Medical Review Board consists of licensed U.S. clinicians—including Medical Doctors (MDs), Nurse Practitioners (NPs), and Clinical Pharmacists—with specific, deep-seated expertise in endocrinology, metabolic health, and regenerative medicine. These professionals bring decades of combined clinical experience and a sophisticated understanding of the regulatory landscape to their review process.
The Clinical Review Standard
A medical review at New Blue Health is more than a simple fact-check; it is a comprehensive assessment of clinical context and safety. Our reviewers evaluate content against several key criteria:
- Clinical Precision: Ensuring that all data points, molecular mechanisms of action, and study outcomes are reported with 100% accuracy and are in strict alignment with current peer-reviewed research.
- Uncompromising Safety Framing: Clearly and prominently identifying potential risks, contraindications, and known adverse effects.
- Clarity of Regulatory Scope: Distinguishing clearly between FDA-approved indications and emerging clinical research or off-label uses.
- Educational Neutrality & Objectivity: Ensuring the content remains strictly objective and does not make unsubstantiated health claims.
Conflict of Interest & Review Frequency
New Blue Health maintains a strict, zero-tolerance conflict of interest policy. Our medical reviewers are required to disclose any financial interests in the pharmaceutical or wellness industries that could potentially influence their clinical judgment.
We perform comprehensive reviews of our core clinical pages at least annually. However, in the rapidly evolving landscape of peptide science and metabolic medicine, we perform ad-hoc clinical reviews whenever major clinical trials release new data or when regulatory agencies like the FDA issue new guidance.
This content is educational and does not replace individualized medical advice. Treatment decisions should be made with a licensed clinician based on personal history, risk profile, and appropriate monitoring.
Medical review & editorial standards
This page is educational content from the New Blue Health Clinical Content Team. It is reviewed under the New Blue Health Medical Review Policy and Editorial Policy and should not replace individualized medical advice from a licensed clinician. For how we evaluate evidence, see Evidence Methodology and Clinical Sources & References.